Trial reportLipids2005
Effects of specific CLA isomers on plasma fatty acid profile and expression of desaturases in humans.
Trial report in Lipids, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 27 citations in OpenAlex.
- Trial
- The Effect of Diet Supplementation with Pomegranate and Bitter Melon on Lipidomic Profile of Serum and Cancerous Tissues of Rats with Mammary Tumours.Antioxidants (Basel, Switzerland) · 2020Article
- Article
- Article
- Effects of cis-9,trans-11 and trans-10,cis-12 CLA isomers on liver and adipose tissue fatty acid profile in hamsters.Lipids · 2006Article
- Article
- Effects of cis-9,trans-11 CLA in rats at intake levels reported for breast-fed infants.Lipids · 2006Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Human studies suggest that CLA changes metabolism, possibly through effects on mRNA expression of desaturase and elongase enzymes. In this respect, differential effects of the two most common dietary CLA isomers, cis-9,trans-11 (c9,t11) and trans-10,cis-12 (t10,c12) CLA, have hardly been studied. We therefore gave 25 healthy, overweight men and women daily for 6 wk a drinkable dairy product containing 3 g of oil that was rich in oleic acid. For the next 18 wk, the control group (n = 7) continued to use this product, whereas the second (n = 9) and third groups (n = 9) received products with 3 g of purified c9,t11 CLA or t10,c12 CLA. For each gram of c9,t11 CLA consumed, the proportion in plasma phospholipids increased by 0.26%. For t10, c12 CLA, this value was 0.20%. The t10,c12 CLA isomer increased plasma TAG levels of conjugated 18:3, whereas c9,t11 CLA increased those of both conjugated 18:3 and 20:3. In plasma phospholipids, the delta9 desaturation index of 18:0 (18:1 n-9/18:0) was decreased by t10,c12 CLA (P= 0.03 for diet effects), and the delta6 desaturation index [(18:3n-6 + 20:3n-6)/18:2n-6] was decreased by both CLA isomers (P < 0.01 for diet effects). The delta5 desaturation index (20:4n-6/20:3n-6) and the delta9 desaturation index of 16:0 (16:1 n-7/16:0) were not affected. No effects were seen on mRNA expression of desaturases and elongase in peripheral blood mononuclear cells (PBMC). We therefore conclude that incorporation of c9,t11 and t10,c12 CLA into plasma lipids reflects dietary intakes. Compared with oleic acid, delta9 and delta6 desaturation indices in plasma phospholipids are decreased after consumption of c9,t11 or t10,c12 CLA. Effects on desaturation indices were, however, not reflected by changes at the transcriptional level for the various desaturases and elongase enzymes in PBMC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.